Nasal GLP-1 startup LionBio raises $6M pre-seed
What's the deal? LionBioDealroom has a profile for this one. Try Dealroom → Therapeutics has raised a $6 million pre-seed round with participation from South Park Commons. The startup is developing nanoparticle-based GLP-1 treatments delivered through the nose, with its first candidate a nasal formulation of semaglutide — the ingredient in Ozempic and Wegovy.
What's the endgame? LionBio plans to start with semaglutide, then expand into peptide treatments for neurological conditions such as addiction, memory, sleep, and dementia. Its formulation targets the olfactory epithelium in the upper nasal cavity, using biodegradable polymer nanoparticles to carry drugs toward the brain.
The technology stems from 30 years of drug-delivery research by co-founder Kam Leong, a Columbia University professor with more than 60 patents and over 80,000 citations. Chief executive officer Robin Guo, who helped build a16z's Speedrun program, left to start the company roughly a year ago.
Why now? Guo called GLP-1 the biggest business opportunity outside AI, noting that Ozempic and Zepbound earned more last year than OpenAI and Anthropic, and that Eli Lilly became the first drugmaker to pass a $1 trillion market cap.
What could go wrong? LionBio is still preclinical. It says its own animal studies showed higher efficacy and fewer side effects such as nausea than pills, but safety and effectiveness in humans remain unproven. The company is scaling manufacturing in Germany and running animal trials in China.
By the numbers: The round sits around the 91st percentile for seed-stage health rounds in the US, an outsized sum for a company before any clinical readout.
The signal: GLP-1 competition is shifting from injections to pills and now to new delivery routes. Rivals including MetP PharmaDealroom has a profile for this one. Try Dealroom → and Aptar are chasing nasal delivery, while obesity drug developers such as Kailera Therapeutics ($1 billion raised) and Moonwalk Biosciences draw heavy funding. LionBio's raise shows investor appetite for the next generation of delivery — but clinical proof and real differentiation from pills and injections will decide its value.
Read more: wowtale.net
Image credit: Lionbio
